Tourmaline Bio Inc. (TRML)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.23B
Last updated: Nov 06, 2026 at 4:00 PM ET
Tourmaline Bio Inc. (TRML) Financials: Revenue, Profit and Cash Flow
Tourmaline Bio reported revenue of $0 for the fiscal year ended Dec 31, 2024. That year, net income was -$73.21M, operating cash flow was -$77.26M and free cash flow was -$77.27M. The quarter ended Jun 30, 2025 had revenue of $0 and net income of -$23.09M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2024, with an operating loss of $89.73M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2024, the net loss widened from the year before. In the quarter ended Jun 2025, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $379.00K |
| Gross profit | $0 | $0 | $0 | $0 | $0 | -$379.00K |
| Research and development | $66.98M | $32.37M | $17.53M | $34.24M | $15.28M | $13.37M |
| Operating income | -$89.73M | -$45.41M | -$19.70M | -$47.51M | -$22.68M | -$18.38M |
| Net income | -$73.21M | -$42.12M | -$19.70M | -$47.83M | -$22.71M | -$18.16M |
| EBITDA | N/A | N/A | -$19.70M | -$46.46M | -$22.14M | -$17.78M |
Quarterly
| Line item | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $40.00K | $0 | $0 | $0 | $2.28M | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $20.00K | $0 | $0 | $0 | $1.14M | $0 | $0 | $0 | -$553.00K | $0 |
| Operating income | -$25.97M | -$26.23M | -$25.81M | -$24.44M | -$21.97M | -$17.52M | -$14.89M | -$6.64M | -$16.37M | -$7.50M | $36.95M | -$19.82M |
| Net income | -$23.09M | -$22.97M | -$22.23M | -$20.18M | -$17.49M | -$13.31M | -$12.90M | -$5.59M | -$16.13M | -$7.50M | $35.66M | -$19.01M |
Balance Sheet
As of Dec 2024, cash and equivalents exceeded short-term debt of $227.00K by $30.28M.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
| Total assets | $309.00M | $210.29M | $9.10M | $251.42M | $152.78M | $41.94M |
| Current assets | $268.84M | $208.87M | $8.31M | $246.51M | $150.75M | $40.79M |
| Cash and equivalents | $30.51M | $140.73M | $8.26M | $18.61M | $17.59M | $38.98M |
| Total liabilities | $8.95M | $5.25M | $1.71M | $8.61M | $4.77M | $2.35M |
| Short-term debt | $227.00K | $221.00K | $162.00K | $150.00K | N/A | N/A |
| Shareholder equity | $300.05M | $205.04M | -$19.73M | $242.81M | -$38.15M | $39.59M |
Quarterly
| Line item | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $269.30M | $287.50M | $309.00M | $328.45M | $344.79M | $359.17M | $210.29M | $151.06M | $159.12M | $172.61M | $9.10M | $206.54M |
| Total liabilities | $10.10M | $7.63M | $8.95M | $7.38M | $6.51M | $5.03M | $5.25M | $8.19M | $10.69M | $10.88M | $28.83M | $11.68M |
| Cash and equivalents | $31.42M | $35.33M | $30.51M | $35.01M | $70.15M | $98.29M | $140.73M | $67.08M | $18.35M | $24.22M | $8.26M | $18.47M |
| Shareholder equity | $259.19M | $279.86M | $300.05M | $321.07M | $338.28M | $354.14M | $205.04M | $142.87M | $148.43M | $161.73M | -$19.73M | $194.87M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2024.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$77.26M | -$28.08M | -$6.46M | -$39.99M | -$19.21M | -$17.66M |
| Capital expenditures | $9.00K | $56.00K | $68.00K | $2.44M | $1.29M | $562.00K |
| Free cash flow | -$77.27M | -$28.14M | -$6.53M | -$42.42M | -$20.50M | -$18.22M |
| Share repurchases | $4.00K | $0 | N/A | $12.86B | $526.00K | N/A |
| Investing cash flow | -$194.31M | $3.84M | -$5.07M | -$96.39M | -$133.30M | -$562.00K |
| Financing cash flow | $161.35M | $156.72M | $19.85M | $137.40M | $131.12M | $36.20M |
Quarterly
| Line item | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$20.26M | -$21.68M | -$20.89M | -$23.44M | -$18.01M | -$14.92M | -$9.35M | -$5.40M | -$9.54M | -$3.79M | $40.53M |
| Capital expenditures | $7.00K | $9.00K | $9.00K | $0 | $0 | $0 | $2.00K | $17.00K | $13.00K | $24.00K | $2.71M |
| Free cash flow | -$20.27M | -$21.69M | -$20.90M | -$23.44M | -$18.01M | -$14.92M | -$9.36M | -$5.41M | -$9.55M | -$3.81M | $37.82M |
Frequently Asked Questions About TRML
What is Tourmaline Bio's annual revenue?
Tourmaline Bio reported revenue of $0 for the fiscal year ended Dec 31, 2024.
Is Tourmaline Bio profitable?
No. Tourmaline Bio reported net income of -$73.21M for the fiscal year ended Dec 31, 2024.
How much free cash flow does TRML generate?
For the fiscal year ended Dec 31, 2024, operating cash flow of -$77.26M minus capital expenditures of $9.00K produced free cash flow of -$77.27M.
How much debt does Tourmaline Bio have?
The balance sheet dated Dec 31, 2024 reported short-term debt of $227.00K and cash and equivalents of $30.51M.
TRML pages: Overview, Financials